BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lozupone M, Solfrizzi V, D'Urso F, Di Gioia I, Sardone R, Dibello V, Stallone R, Liguori A, Ciritella C, Daniele A, Bellomo A, Seripa D, Panza F. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. Expert Opin Emerg Drugs 2020;25:319-35. [PMID: 32772738 DOI: 10.1080/14728214.2020.1808621] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Song H, Yang J, Yu W. Promoter Hypomethylation of TGFBR3 as a Risk Factor of Alzheimer’s Disease: An Integrated Epigenomic-Transcriptomic Analysis. Front Cell Dev Biol 2022;9:825729. [DOI: 10.3389/fcell.2021.825729] [Reference Citation Analysis]
2 Wen J, Liu D, Zhao L. Small molecules targeting γ-secretase and their potential biological applications. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mak S, Li W, Fu H, Luo J, Cui W, Hu S, Pang Y, Carlier PR, Tsim KW, Pi R, Han Y. Promising tacrine/huperzine A-based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget. J Neurochem 2021. [PMID: 33930191 DOI: 10.1111/jnc.15379] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Owens L, Bracewell J, Benedetto A, Dawson N, Gaffney C, Parkin E. BACE1 Overexpression Reduces SH-SY5Y Cell Viability Through a Mechanism Distinct from Amyloid-β Peptide Accumulation: Beta Prime-Mediated Competitive Depletion of sAβPPα. J Alzheimers Dis 2022. [PMID: 35180123 DOI: 10.3233/JAD-215457] [Reference Citation Analysis]
5 Mota IFL, de Lima LS, Santana BM, Gobbo GAM, Bicca JVML, Azevedo JRM, Veras LG, Taveira RAA, Pinheiro GB, Mortari MR. Alzheimer's Disease: Innovative Therapeutic Approaches Based on Peptides and Nanoparticles. Neuroscientist 2021;:10738584211016409. [PMID: 34018874 DOI: 10.1177/10738584211016409] [Reference Citation Analysis]
6 Bomasang-Layno E, Bronsther R. Diagnosis and Treatment of Alzheimer's Disease:: An Update. Dela J Public Health 2021;7:74-85. [PMID: 34604768 DOI: 10.32481/djph.2021.09.009] [Reference Citation Analysis]
7 Purgatorio R, Gambacorta N, Catto M, de Candia M, Pisani L, Espargaró A, Sabaté R, Cellamare S, Nicolotti O, Altomare CD. Pharmacophore Modeling and 3D-QSAR Study of Indole and Isatin Derivatives as Antiamyloidogenic Agents Targeting Alzheimer's Disease. Molecules 2020;25:E5773. [PMID: 33297547 DOI: 10.3390/molecules25235773] [Reference Citation Analysis]
8 Zhang Q, Song Q, Gu X, Zheng M, Wang A, Jiang G, Huang M, Chen H, Qiu Y, Bo B, Tong S, Shao R, Li B, Wang G, Wang H, Hu Y, Chen H, Gao X. Multifunctional Nanostructure RAP-RL Rescues Alzheimer's Cognitive Deficits through Remodeling the Neurovascular Unit. Adv Sci (Weinh) 2021;8:2001918. [PMID: 33511002 DOI: 10.1002/advs.202001918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pardridge WM. Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery. Pharmaceuticals (Basel) 2020;13:E394. [PMID: 33207605 DOI: 10.3390/ph13110394] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
10 Doggrell SA. Still grasping at straws: donanemab in Alzheimer's disease. Expert Opin Investig Drugs 2021;30:797-801. [PMID: 34162295 DOI: 10.1080/13543784.2021.1948010] [Reference Citation Analysis]
11 Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Buzoianu AD, Sahib S, Tian ZR, Bryukhovetskiy I, Manzhulo I, Menon PK, Patnaik R, Wiklund L, Sharma A. Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Prog Brain Res 2021;265:1-97. [PMID: 34560919 DOI: 10.1016/bs.pbr.2021.04.008] [Reference Citation Analysis]
12 Lozupone M, Berardino G, Mollica A, Sardone R, Dibello V, Zupo R, Lampignano L, Castellana F, Bortone I, Stallone R, Daniele A, Altamura M, Bellomo A, Solfrizzi V, Panza F. ALZT-OP1: An experimental combination regimen for the treatment of Alzheimer's Disease. Expert Opin Investig Drugs 2022. [PMID: 35758153 DOI: 10.1080/13543784.2022.2095261] [Reference Citation Analysis]
13 Johnson NE, Greene E. Neurologic Therapeutics in 2035: The Neurology Future Forecasting Series. Neurology 2021;97:1121-7. [PMID: 34903613 DOI: 10.1212/WNL.0000000000012976] [Reference Citation Analysis]
14 Li S, Stern AM. Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities. Mol Psychiatry 2022. [PMID: 35484241 DOI: 10.1038/s41380-022-01589-5] [Reference Citation Analysis]
15 La Barbera L, Mauri E, D’amelio M, Gori M. Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer’s disease: Current trends and future perspectives. Front Neurosci 2022;16:939855. [DOI: 10.3389/fnins.2022.939855] [Reference Citation Analysis]
16 Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y. The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review. J Alzheimers Dis 2021. [PMID: 34924395 DOI: 10.3233/JAD-215423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Lichlyter DA, Krumm ZA, Golde TA, Doré S. Role of CRF and the hypothalamic-pituitary-adrenal axis in stroke: revisiting temporal considerations and targeting a new generation of therapeutics. FEBS J 2022. [PMID: 35108458 DOI: 10.1111/febs.16380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hu B, Geng C, Guo F, Liu Y, Zong YC, Hou XY. GABAA receptor agonist muscimol rescues inhibitory microcircuit defects in the olfactory bulb and improves olfactory function in APP/PS1 transgenic mice. Neurobiol Aging 2021;108:47-57. [PMID: 34507271 DOI: 10.1016/j.neurobiolaging.2021.08.003] [Reference Citation Analysis]
19 Xia C, Ma Q. The Levels of Amyloid β-Protein and P181 in Peripheral Blood of Patients with Alzheimer's Disease Combined with Helicobacter pylori Infection and Their Clinical Significance. Comput Math Methods Med 2021;2021:7135399. [PMID: 34966443 DOI: 10.1155/2021/7135399] [Reference Citation Analysis]
20 Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, Meyfour A, Sheriff S, Shen T, Dhiman K, Ghasem HS, Paul AH, Stuart LG, Mirzaei M. Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease. Aging Dis 2021;12:1964-76. [PMID: 34881080 DOI: 10.14336/AD.2021.0719] [Reference Citation Analysis]
21 Colca JR, Finck BN. Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches. Front Mol Biosci 2022;9:929328. [DOI: 10.3389/fmolb.2022.929328] [Reference Citation Analysis]
22 Altuna M, Olmedo-Saura G, Carmona-Iragui M, Fortea J. Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications. Int J Mol Sci 2022;23:4307. [PMID: 35457126 DOI: 10.3390/ijms23084307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Tombini M, Assenza G, Ricci L, Lanzone J, Boscarino M, Vico C, Magliozzi A, Di Lazzaro V. Temporal Lobe Epilepsy and Alzheimer's Disease: From Preclinical to Clinical Evidence of a Strong Association. J Alzheimers Dis Rep 2021;5:243-61. [PMID: 34113782 DOI: 10.3233/ADR-200286] [Reference Citation Analysis]